HBV transcription and translation persist despite viral suppression in HBV‐HIV co‐infected patients on antiretroviral therapy
Mauricio Lisker‐Melman, Abdus S. Wahed, Marc G. Ghany, Raymond T. Chung, Wendy C. King, David E. Kleiner, Atul K. Bhan, Mandana Khalili, Mamta K. Jain, Mark Sulkowski, David K. Wong, Gavin Cloherty, Richard K. Sterling – 29 June 2022
Long‐term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States
Peter Lymberopoulos, Sameer Prakash, Anjiya Shaikh, Anshul Bhatnagar, Anthony K. Allam, Karthik Goli, John A. Goss, Fasiha Kanwal, Abbas Rana, Kris V. Kowdley, Prasun Jalal, George Cholankeril – 29 June 2022 – There have been conflicting data regarding liver transplantation (LT) outcomes for hereditary hemochromatosis (HH), with no recent data on LT outcomes in patients with HH in the past decade. Using the United Network for Organ Sharing registry, we evaluated waitlist and post‐LT survival in all adult patients listed for HH without concomitant liver disease from 2003 to 2019.
Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study
Byungyoon Yun, Sang Hoon Ahn, Jin‐Ha Yoon, Beom Kyung Kim – 28 June 2022 – Many studies have elucidated the protective associations of statin use with liver cancer or mortality, but studies examining statin's effect on the risk of progression to liver cirrhosis considering medical/metabolic conditions or lifestyle factors are lacking. We aimed to assess statin's benefit independent of conventional risk factors.